Badger Meter Inc vs Novo Nordisk A/S — how do they compare? Badger Meter Inc trades at $134.2 (market cap $3.93B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 52.9× Badger Meter Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| BMI | NVO | |
|---|---|---|
Market Cap | $3.93B | $207.85B |
Sector | Technology | Health |
52-Week High | $193.09 | $63.98 |
52-Week Low | $113.41 | $35.29 |
Enterprise Value | $3.84B | $222.55B |
Dividend Yield | 1.18% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $133.63, down 2.06% amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 14.27% net margin and 18.48% ROE, but faces headwinds from recent securities class action lawsuits and declining revenue projections for 2026. Technical indicators suggest bearish momentum with resistance at $137-$139 levels.
While BMI maintains solid fundamentals and analyst consensus targets $155.20 (16% upside), near-term risks include legal uncertainties and earnings volatility. The company's water technology focus provides defensive characteristics, but investors should weigh class action litigation risks against the stock's valuation premium (P/E 31.78).
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →